Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 56%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Natera is a rapidly growing company with a diverse range of products including NIPT, HCS, Signatera, and Prospera, with potential for continued growth and expansion. Its recent successes and focus on sustainability make it a strong candidate for long-term investment. With positive momentum and strong prospects for the future, this company is a favorable choice for investors looking for potential growth and returns in the personalized diagnostics market.

Bears say

Natera is facing increasing competition in the MRD landscape and persistent competitive intensity in the Women's Health market. The company's strong moat based on its reimbursement advantage is at risk as competitors may replicate Natera's reimbursement journey, resulting in increased competition and lower margins for Natera. Additionally, there is a downside risk if MRD penetration stalls or if competitors are perceived as a greater threat than expected. These factors could lead to a decrease in Natera's premium and a potential stock price decline.

Natera (NTRA) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 56% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 16 analysts, Natera (NTRA) has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $260.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $260.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.